Health Benefits and Cost-Effectiveness of Primary ... [Cancer Prev Res (Phila). 2010] - PubMed result

Cancer Prev Res (Phila). 2010 Nov 18. [Epub ahead of print]
Health Benefits and Cost-Effectiveness of Primary Genetic Screening for Lynch Syndrome in the General Population.

Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF, Gruber SB, Burt RW.

Authors' Affiliations: 1Archimedes, Inc., San Francisco, California; 2GI Cancer Research Laboratory, Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas; 3Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 4Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands; 5Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor, Michigan; and 6Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

Abstract

In current clinical practice, genetic testing to detect Lynch syndrome mutations ideally begins with diagnostic testing of an individual affected with cancer before offering predictive testing to at-risk relatives. An alternative strategy that warrants exploration involves screening unaffected individuals via demographic and family histories, and offering genetic testing to those individuals whose risks for carrying a mutation exceed a selected threshold. Whether this approach would improve health outcomes in a manner that is cost-effective relative to current standards of care has yet to be demonstrated. To do so, we developed a simulation framework that integrated models of colorectal and endometrial cancers with a 5-generation family history model to predict health and economic outcomes of 20 primary screening strategies (at a wide range of compliance levels) aimed at detecting individuals with mismatch repair gene mutations and their at-risk relatives. These strategies were characterized by (i) different screening ages for starting risk assessment and (ii) different risk thresholds above which to implement genetic testing. For each strategy, 100,000 simulated individuals, representative of the U.S. population, were followed from the age of 20, and the outcomes were compared with current practice. Findings indicated that risk assessment starting at ages 25, 30, or 35, followed by genetic testing of those with mutation risks exceeding 5%, reduced colorectal and endometrial cancer incidence in mutation carriers by approximately 12.4% and 8.8%, respectively. For a population of 100,000 individuals containing 392 mutation carriers, this strategy increased quality-adjusted life-years (QALY) by approximately 135 with an average cost-effectiveness ratio of $26,000 per QALY. The cost-effectiveness of screening for mismatch repair gene mutations is comparable to that of accepted cancer screening activities in the general population such as colorectal cancer screening, cervical cancer screening, and breast cancer screening. These results suggest that primary screening of individuals for mismatch repair gene mutations, starting with risk assessment between the ages of 25 and 35, followed by genetic testing of those whose risk exceeds 5%, is a strategy that could improve health outcomes in a cost-effective manner relative to current practice. Cancer Prev Res; 4(1): 1-13. ©2010 AACR.

PMID: 21088223 [PubMed - as supplied by publisher]
Health Benefits and Cost-Effectiveness of Primary ... [Cancer Prev Res (Phila). 2010] - PubMed result